Latest Insights - page 56 | BiopharmaTrend

Superluminal Medicines Raises $120 Million to Advance GPCR-Targeted Drug Discovery

Superluminal Medicines, Inc. has raised $120 million in a Series A funding round led by RA Capital Management, with participation from Insight Partners, NVentures, Catalio Capital Management, Eli Lilly and …

Continue ›››

Rethinking Clinical Trials: Tim Smith on Medable’s Approach to Speed and Efficiency

As the demand for decentralized and hybrid clinical trials rises, Medable Inc. is positioning itself at the forefront of this transformation. Known for its cloud-based platform, Medable has facilitated over …

Continue ›››

Eli Lilly Partners with Genetic Leap in $409 Million AI-Driven Drug Discovery Deal

Eli Lilly has announced a partnership with Genetic Leap, a biotech company specializing in RNA-targeted drug discovery using AI models. The collaboration is valued at up to $409 million, including …

Continue ›››

ETH Zurich’s Flexible Brain Probes: A Safer Twist in the BCI Journey

Neuralink recently captured the public's attention with the implantation of its brain chip in a second patient, allowing the person to command digital devices with mere thoughts. This achievement represents …

Continue ›››

Proscia Expands Concentriq Platform with Real-World Data to Enhance Precision Medicine

Proscia has announced a new real-world data offering on its Concentriq platform, integrating over 10 million de-identified pathology images with clinical and genomic data. This addition provides life sciences organizations …

Continue ›››

BioAge Labs Files for IPO with Focus on Anti-Aging Therapeutics and Metabolic Diseases

BioAge Labs, a clinical-stage biopharmaceutical company specializing in anti-aging and metabolic disease therapeutics, has filed for an initial public offering (IPO). The company is led by CEO Kristen Fortney and …

Continue ›››

Noetik Secures $40 Million Series A to Accelerate AI-Driven Precision Cancer Therapies

Noetik, an emerging biotech firm specializing in the application of artificial intelligence (AI) to oncology, has announced the successful closure of a $40 million Series A financing round. The funding …

Continue ›››

Brinter AM to Launch 3D Bioprinter to the International Space Station

Brinter AM Technologies Oy has been selected to provide a 3D bioprinter for a European Space Agency (ESA) project aimed at advancing tissue manufacturing capabilities on the International Space Station …

Continue ›››

Novartis' Phase III V-MONO Trial Demonstrates Efficacy of Leqvio in Reducing LDL-C in ASCVD Patients

Novartis has announced that its Phase III V-MONO clinical trial evaluating the small interfering RNA (siRNA) therapy Leqvio (inclisiran) in patients with low or moderate risk of atherosclerotic cardiovascular disease …

Continue ›››

Flagship Pioneering and Quotient Therapeutics Partner with Pfizer to Advance Research in Cardiovascular and Renal Diseases

Flagship Pioneering and its subsidiary Quotient Therapeutics have announced a new research initiative under their strategic partnership with Pfizer to identify potential therapeutic targets for cardiovascular and renal diseases. This …

Continue ›››

Bayer and NextRNA Therapeutics Partner to Develop Novel Small Molecule Drugs Targeting Long Non-Coding RNA in Cancer

Bayer and NextRNA Therapeutics have entered a strategic partnership to develop a new class of small molecule drugs targeting cancers driven by dysregulated long non-coding RNA (lncRNA). The collaboration could …

Continue ›››

US Allocates $50 Million to HP's Microfluidics Semiconductor Fab

The US Department of Commerce has committed up to $50 million to HP for expanding its microfluidics semiconductor fabrication facility in Corvallis, Oregon. The funding, part of the CHIPS and …

Continue ›››